Nos publications

Découvrez nos dernières ressources, idées et avis d’experts. Rubrique regroupant nos réflexions sur nos différents secteurs d’expertises.

Tendances

The Growth Blueprint podcast
Automotive Study
The new economics of neobanking
Better Health
Global Pricing Study 2025
Tariffs, pricing, and power
IA Generative
40 years of Better Growth in industrials
Better Growth
Global
Blog header image_Beyond pricing: How MFN may reshape pharma dealmaking
Jun 08, 2026 | Blog

How MFN may reshape pharma dealmaking beyond pricing

Healthcare & Life Sciences Pharma & Biotechnology
Americas
MFN puts pharma between Scylla and Charybdis
Jun 03, 2026 | Blog

MFN puts pharma between Scylla and Charybdis

Healthcare & Life Sciences Pharma & Biotechnology
Simon-Kucher insights: End-to-end AI-enabled omnichannel engagement in medtech and diagnostics
Jun 02, 2026 | Blog

End-to-end AI-enabled omnichannel engagement in medtech and diagnostics

Healthcare & Life Sciences Diagnostics
Middle east & APAC
Mockup of whitepaper
Jun 01, 2026 | Perspective | Whitepaper

Financing access to medicines in emerging markets

Healthcare & Life Sciences Healthcare Providers
Simon-Kucher insights: AI in pharma brand strategy
May 28, 2026 | Perspective | Whitepaper

AI in pharma brand strategy

Healthcare & Life Sciences Pharma & Biotechnology
Middle east & APAC
Simon-Kucher insights: How RWE in reshaping China market access
May 15, 2026 | Blog

How RWE is reshaping China market access

Healthcare & Life Sciences Pharma & Biotechnology
Simon-Kucher insights_Smart moves in Clinical Decision Support investments
May 12, 2026 | Blog

Smart moves in Clinical Decision Support investments

Healthcare & Life Sciences Diagnostics
Americas
Simon-Kucher insights: MFN was never just about lower US prices
May 06, 2026 | Blog

MFN was never just about lower US prices

Healthcare & Life Sciences Pharma & Biotechnology
Americas
Simon-Kucher insights: FY IPPS 2027 proposed rule
Apr 28, 2026 | Blog

FY IPPS 2027 proposed rule

Healthcare & Life Sciences Pharma & Biotechnology
Americas
Simon-Kucher insights: MFN pricing: GENEROUS 8 launch strategy
Apr 23, 2026 | Blog

MFN pricing: GENEROUS 8 launch strategy

Healthcare & Life Sciences Pharma & Biotechnology
China
Simon-Kucher insights: China medtech 2026 outlook
Apr 17, 2026 | Blog

China medtech 2026 outlook

Healthcare & Life Sciences Medtech
Global
Simon-Kucher insights: Pricing-access split: choosing the right model
Apr 16, 2026 | Blog

Pricing-access split: choosing the right organizational model

Healthcare & Life Sciences Pharma & Biotechnology
Americas
Simon-Kucher insights: MFN pricing: Comparing comment letters on GUARD and GLOBE
Apr 16, 2026 | Blog

MFN pricing: Comparing comment letters on GUARD and GLOBE

Healthcare & Life Sciences Pharma & Biotechnology
Americas
Simon-Kucher insights: Analyzing stakeholder comments on the GLOBE model
Apr 14, 2026 | Blog

Analyzing stakeholder comments on the GLOBE model

Healthcare & Life Sciences Pharma & Biotechnology
Simon-Kucher insights: Beyond the pill: Capturing value in preventive healthcare
Apr 01, 2026 | Blog

Beyond the pill: Capturing value in preventive healthcare

Healthcare & Life Sciences Consumer Healthcare
Americas
Simon-Kucher insights_Analyzing 159 comment letters on the GUARD model
Apr 01, 2026 | Blog

Analyzing 159 comment letters on the GUARD model

Healthcare & Life Sciences Pharma & Biotechnology
Langue
Rechercher